The psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.

Two biotech companies are highlighted as standout investments for 2026. Axsome Therapeutics has strong late-stage pipeline developments with FDA acceptance of supplemental applications for AXS-05 in Alzheimer's agitation treatment and support for AXS-12 for narcolepsy, with 19 of 20 analysts rating it a Buy and targeting 8% upside. Innoviva received FDA approval for Nuzolvence, a first-in-class oral antibiotic for gonorrhea with significant market potential, and has shown strong financial performance with analyst consensus price target nearly double current trading levels.

The Motley Fool recommends two biotech stocks for long-term investment: Axsome Therapeutics, which has generated strong revenue growth (65.8% YoY through Q3 2025) with approved products and promising late-stage candidates including Auvelity for Alzheimer's disease agitation; and Exelixis, an oncology specialist with its blockbuster drug Cabometyx and an upcoming next-generation cancer medicine Zanzalintinib in phase 3 trials for metastatic colorectal cancer.

Axsome Therapeutics announced that the FDA has accepted and granted Priority Review designation to its supplemental NDA for AXS-05 for treating Alzheimer's disease agitation, with a PDUFA target action date of April 30, 2026. The drug addresses a significant unmet medical need, as up to 76% of Alzheimer's patients experience agitation. AXS-05 previously received Breakthrough Therapy designation in June 2020.

The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.

Axsome Therapeutics will participate in two investor conferences in December 2025, including the Piper Sandler Healthcare Conference and BofA Securities CNS Therapeutics Virtual Conference, presenting their latest developments in central nervous system treatments.

Two biotech companies, Axsome Therapeutics and Exelixis, are predicted to potentially outperform the market in the next five years due to strong product portfolios, promising drug pipelines, and potential for significant market expansion in healthcare treatments.

Law firm Johnson Fistel is investigating potential legal violations by officers of General Motors, DocGo, Estée Lauder, and Axsome Therapeutics, with class action lawsuits surviving motions to dismiss.

Axsome Therapeutics announced participation in multiple healthcare investor conferences in September 2025, including Wells Fargo, Cantor, Morgan Stanley, and others, presenting fireside chats and investor meetings.

Axsome Therapeutics is joining the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during Alzheimer's & Brain Awareness Month.

Axsome Therapeutics presented multiple studies on its sleep disorder treatments AXS-12 and solriamfetol at the SLEEP 2025 conference, showcasing the company's innovation in this therapeutic area.

The article discusses two biotech companies, Summit Therapeutics and Axsome Therapeutics, that have seen significant stock price gains in recent years. Despite their recent performance, the author believes there is still potential upside for investors in these companies.